Luminal A tumors portend the most favorable outcomes; basal-like (triple-negative) cancers are associated with higher rates of local recurrence and early distant metastasis; and HER2-enriched tumors derive considerable benefit from targeted therapy [6]. The gene discussed is ERBB2; the disease is cancer.